Gemfibrozil
- CAS No.
- 25812-30-0
- Chemical Name:
- Gemfibrozil
- Synonyms
- lopid;2,2-Dimethyl-5-(2,5-Dimethylphenoxy)Valeric;CI-7;Jezil;Genlip;C1-719;Lipttr;ci-719;Lipozid;Decrelip
- CBNumber:
- CB9154247
- Molecular Formula:
- C15H22O3
- Molecular Weight:
- 250.33
- MOL File:
- 25812-30-0.mol
- Modify Date:
- 2024/5/8 14:48:35
| Melting point | 61-63°C |
|---|---|
| Boiling point | 158-159 C |
| Density | 1.1109 (rough estimate) |
| refractive index | 1.5020 (estimate) |
| storage temp. | 2-8°C |
| solubility | Practically insoluble in water, very soluble in methylene chloride, freely soluble in anhydrous ethanol and in methanol. |
| form | powder |
| pka | 4.75±0.45(Predicted) |
| color | White to Off-White |
| Water Solubility | >0.5g/L(temperature not stated) |
| Merck | 14,4388 |
| BCS Class | 2 |
| CAS DataBase Reference | 25812-30-0(CAS DataBase Reference) |
| IARC | 3 (Vol. 66) 1996 |
| EPA Substance Registry System | Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- (25812-30-0) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302 | |||||||||
| Precautionary statements | P301+P312+P330 | |||||||||
| Hazard Codes | Xn,Xi | |||||||||
| Risk Statements | 22-63-62-46-36/38-21 | |||||||||
| Safety Statements | 36-53-36/37-26-25 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | YV7120000 | |||||||||
| HazardClass | IRRITANT | |||||||||
| HS Code | 2918992090 | |||||||||
| Toxicity | LD50 in mice, rats (mg/kg): 3162, 4786 orally (Kurtz) | |||||||||
| NFPA 704 |
|
Gemfibrozil price More Price(6)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | PHR1286 | Gemfibrozil Pharmaceutical Secondary Standard; Certified Reference Material | 25812-30-0 | 1G | ₹8107.93 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | G9518 | Gemfibrozil | 25812-30-0 | 5G | ₹9666.73 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | G9518 | Gemfibrozil | 25812-30-0 | 25G | ₹32052.83 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 91823 | Gemfibrozil analytical standard | 25812-30-0 | 100MG | ₹5260.95 | 2022-06-14 | Buy |
| TCI Chemicals (India) | G0368 | Gemfibrozil min. 98.0 % | 25812-30-0 | 5G | ₹6800 | 2022-05-26 | Buy |
Gemfibrozil Chemical Properties,Uses,Production
Description
Gemfibrozil is a peroxisome proliferator-activated receptor α (PPARα) and PPARγ agonist (EC50s = 193.3 and 147.8 μM, respectively, in transactivation assays). In vivo, gemfibrozil (50 mg/kg, p.o.) reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia. Gemfibrozil (100 mg/kg per day) reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C) motif ligand 2 (CCL2) in ApoE-/- mice. Formulations containing gemfibrozil have been used in the treatment of high cholesterol.
Chemical Properties
White Crystalline Powder
Uses
Gemfibrozil has been used to to study its effects on cell cycle progression in yeast. It has been used to study the effects of fibrates on cell proliferation and gene expression in human cell lines.
World Health Organization (WHO)
Gemfibrozil, an antihyperlipidaemic derivative of clofibrate, was introduced in the early 1980's. It is registered in several countries for the treatment of hyperlipidaemia unresponsive to dietary measures. (See also the WHO comment for clofibrate).
General Description
Gemfibrozil, 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid (Lopid), is a congener of clofibratethat was used first in the treatment of hyperlipoproteinemia inthe mid-1970s. Its mechanism of action and use are similar tothose of clofibrate. Gemfibrozil reduces plasma levels ofVLDL triglycerides and stimulates clearance of VLDL fromplasma. The drug has little effect on cholesterol plasma levelsbut does cause an increase of HDL.
Gemfibrozil is absorbed quickly from the gut and excretedunchanged in the urine. The drug has a plasma half-life of1.5 hours, but reduction of plasma VLDL concentration takesbetween 2 and 5 days to become evident. The peak effect of its hypolipidemic action may take up to 4 weeks to becomemanifest.
Mechanism of action
From the chemical point of view, gemfibrozil is somewhat related to clofibrate and has analogous pharmacological use. The primary action of gemibrozil as well as clofibrate consists of a significant reduction in the level of very low-density proteins in the plasma and an increase in high-density protein formation.
Gemfibrozil Preparation Products And Raw materials
Raw materials
1of4
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Cadila Pharmaceuticals Ltd | +91-7069076657 +91-7069076657 | Ahmedabad, India | 54 | 58 | Inquiry |
| ANWITA APIS | +919000311012 | Hyderabad, India | 198 | 58 | Inquiry |
| Apotex Pharmachem India Pvt Ltd | +91-8022891034 +91-8022891000 | Karnataka, India | 109 | 58 | Inquiry |
| Hikal Ltd. | +91-9538444622 +91-8067356100 | Maharashtra, India | 31 | 58 | Inquiry |
| Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
| Sachem | 91-9810014878 | Delhi, India | 75 | 58 | Inquiry |
| Vapoor Chemicals | 91-22-26590197 | Maharashtra, India | 71 | 58 | Inquiry |
| PIRAMAL PHARMA LTD | +91-22-3802 3000 | New Delhi, India | 28 | 58 | Inquiry |
| OCEAN TRADING CORPORATION | +91(22) 24921669 | New Delhi, India | 6211 | 58 | Inquiry |
| CADILA PHARMACEUTICALS LTD | +91 2714 220315 | New Delhi, India | 32 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| Cadila Pharmaceuticals Ltd | 58 |
| ANWITA APIS | 58 |
| Apotex Pharmachem India Pvt Ltd | 58 |
| Hikal Ltd. | 58 |
| Ralington Pharma | 58 |
| Sachem | 58 |
| Vapoor Chemicals | 58 |
| PIRAMAL PHARMA LTD | 58 |
| OCEAN TRADING CORPORATION | 58 |
| CADILA PHARMACEUTICALS LTD | 58 |
25812-30-0(Gemfibrozil)Related Search:
1of4
chevron_right